NEW YORK, July 08, 2021 (World NEWSWIRE) — GBS (Nasdaq: GBS), a existence sciences organization producing non-invasive, genuine-time diagnostic tests for clients and their main well being practitioners at point-of-treatment, currently declared it has been awarded a USD $4.7 million, Australian Federal Government scientific grant to fund the establish out of a Biosensor production facility. This undertaking has been identified as 1 of six National Manufacturing Priorities determined by the Authorities under Modern day Production Technique (MMS).
The Health-related Merchandise Priority Grant, from the Australian Federal Government’s Division of Industry, Science, Electricity and Resources’ Fashionable Producing Initiative will guidance the establishment of an Australian large tech health-related unit manufacturing facility to commence scaled output of the Printable Natural Electronic Biosensor know-how for the APAC area.
GBS’s flagship products, the Saliva Glucose Biosensor (SGB), is the first innovation to be created from the Biosensor System and is currently staying formulated as a position-of-treatment examination intended to supply men and women dwelling with diabetic issues a non-invasive alternative to finger-prick blood glucose tests. This substitute test will offer you a soreness-absolutely free selection to present tests methods by utilizing an Natural Skinny-Movie Transistor (OTFT) that creates glucose measurements in serious-time on an application or committed device for the extra than 460 million persons living with diabetic issues around the globe.
Supplementary to the SGB, the Corporation also strategies to commercialize a SARS-CoV-2 Antibody Biosensor speedy position-of-care diagnostic examination to keep an eye on publicity and immunity concentrations in authentic time in the struggle in opposition to COVID-19. The SARS-CoV-2 Biosensor is currently being designed in collaboration with the Wyss Institute for Biologically Encouraged Engineering at Harvard University. The Biosensor will be integrated with the Institute’s eRapid electrochemical sensor technologies to empower simultaneous electrochemical sensing of numerous biomarkers connected to SARS-CoV-2 infection for point-of-treatment COVID-19 diagnostic applications.
The eRapid technological innovation was developed by a cross-disciplinary crew led by Wyss Founding Director Donald Ingber, M.D., Ph.D. and Wyss Senior Staff members Scientist Pawan Jolly, Ph.D. as a reduced-value, affinity-dependent electrochemical sensing system that can simultaneously detect and quantify a wide range of biomarkers, with equally significant sensitivity and specificity, from a tiny volume of saliva or blood.
GBS anticipates its production facility will have ability to create an annual supply of 100M biosensor models for roll-out to key world wide commercialization internet sites in the Asia Pacific (APAC) area.
The need to commence scaled generation of the SGB and SARS-CoV-2 Antibody Biosensor exam follows rigorous testing and research of the know-how supported by Harvard University and the Johns Hopkins Environmental Health Microbiology and Immunology Laboratory at the Johns Hopkins Bloomberg College of Public Health and fitness as well as the lab’s Salivary Biomarkers and Infectious Diseases System.
Following the effective commercialization of the SGB, the biosensor know-how will be customized to extra position-of-care applications, which include prognosis/administration of cancer, infectious disease, and allergy symptoms. In whole, there are at present 130 indications beneath enhancement, all of which look for to permit more healthy communities globally.
GBS’s technological innovation is an Australian invention, resulting from 20 several years of research and progress by Professor Paul Dastoor and his team at the College of Newcastle’s Centre for Organic and natural Electronics. Prof. Dastoor is a world-wide chief in the rising area of Natural and organic Electronics Sensor Printing, which works by using standard roll-to-roll printing technology to produce minimal-price tag medical diagnostics.
“Our whole business design is all about translation of discovery into a products that fills an unmet medical want. Creating a dedicated higher tech production facility to start production for our Glucose Biosensor will gain the regional society by developing jobs, but most importantly the clients troubled with diabetes, who have up until now experienced to finger-prick several moments a day in buy to observe their glucose degrees. This grant could not have arrive at a more suitable time as we prepare for scientific tests,” Team Main Executive Officer of The iQ Group World-wide, Dr. George Syrmalis claimed.
GBS Chief Govt Officer Harry Simeonidis additional, “We are pleased with this substantial grant as it enables us not only to further more advance our technology but also to carry on acquiring upcoming point-of-treatment diagnostic exams. The new significant-tech health care device facility will support neighborhood positions in Australia and let GBS to manufacture health care diagnostic exams for Australia and Asia.”
About GBS Inc.
GBS Inc. is a lifetime sciences corporation building non-invasive, genuine-time checking and diagnostic checks for people and their principal wellness practitioners. With the earth-first Biosensor System, GBS Inc. is creating and launching diagnostic tests urgently wanted to support people today dwelling with diabetes.
About The iQ Team Global
The iQ Group World is a bioscience expenditure consortium that finds, cash and develops bioscience discoveries to generate life-shifting professional medical improvements.
Take a look at our web page: theiqgroupglobal.com
Investor& Media contacts:
LifeSci Advisors, LLC
Jeremy Feffer – Controlling Director
The iQ Group World-wide
James Gorman – Interaction Supervisor
+61 428 112 174